What the business is, and whether it's a good one at a fair price.
Manufactures active pharmaceutical ingredients (APIs) including antibiotics, methylamine, salicylic acid and their derivatives, along with finished formulations and specialty chemicals. Operates a methylamine plant at Sayakha (Bharuch) that reached roughly 1,000 tonnes per month by March 2026 and was at 65% utilization in Q1 FY27, with management targeting 70%+ within a year; the salicylic acid line was halted pending phenol-recovery equipment, while a derivatives plant was set to commission by mid-June. Finished formulations posted revenue of INR91.3 crore in Q4 FY26 (up 41% YoY), and management has guided to a sustainable INR90 crore quarterly run-rate with a goal of INR1,000 crore in 3-5 years. Exports contribute 38% of total revenue, with regulated markets making up 73% of export revenue (up from 66% in FY25); a US FDA metformin DMF has been filed, with flows expected within 12-18 months. Specialty chemicals revenue jumped 150% YoY in Q1 FY27 and OSD capacity at the Baddi facility is set to double. Raw materials are the largest cost item at 58.6% of revenue; planned capex is INR300-400 crore over 2-3 years in a quasi-brownfield model. Q1 FY27 consolidated revenue was INR703.6 crore with EBITDA margin of 13.8%, versus a FY26 margin of 12.15%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from AARTI DRUGS LTD.'s filed financials and exchange disclosures
AARTI DRUGS LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol AARTIDRUGS.
Yes. Over the trailing twelve months AARTI DRUGS LTD. reported a net profit of ₹191 Cr on revenue of ₹2,678 Cr.
Yes. The dividend yield is 0.46% at the current price. It paid out 9% of its profit as dividend in FY26.
No. Debt stands at 0.37× equity, and it carries net debt of ₹568 Cr. That is lower than 27% of its 171 Pharmaceuticals peers.
On trailing P/E, AARTI DRUGS LTD. ranks 58 of 169 in Pharmaceuticals — cheaper than 66% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session AARTI DRUGS LTD. moves 1.09% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by AARTI DRUGS LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
